Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Mucosal Immunity and Vaccine
share announcement

Mucosal Immunity and Vaccine

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Innate and Adaptive Immunity in Vaccination".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 2410

Special Issue Editors

Dr. Xingmin Sun

E-Mail Website
Guest Editor
Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, 12901 Bruce B. Downs Boulevard, MDC07, Tampa, FL 33612, USA
Interests: vaccinology; immunology; applied immunology; mucosal immunology; vaccine platforms; bacterial pathogenesis
Dr. Yongqun He (Oliver)

E-Mail Website
Guest Editor
Unit for Lab Animal Medicine and Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI, USA
Interests: vaccinology; reverse vaccinology; machine learning
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Mucosal surfaces are the first line of defense against numerous infectious agents, yet the development of vaccines targeting these sites has historically been challenging. This Special Issue will address the latest advancements and challenges in inducing robust mucosal immune responses through vaccination, with implications for preventing infections such as respiratory, gastrointestinal, and sexually transmitted diseases.

This Special Issue will focus on the critical role of mucosal immunity in vaccine development, exploring how vaccines can be designed to elicit effective immune responses at mucosal surfaces—the primary entry points for many pathogens. In this Special Issue, original research articles, reviews, short communications, and perspectives are welcome.

Topic areas may include (but are not limited to) the following:

  • Mechanisms of mucosal immune responses to vaccines.
  • Development of mucosal vaccines: oral, nasal, and other routes of administration.
  • Comparative efficacy of mucosal versus systemic immunity in infection control.
  • Mucosal adjuvants and delivery systems for enhancing vaccine efficacy.
  • Role of secretory IgA and other mucosal antibodies in vaccine-induced protection.
  • Immune memory and long-term protection conferred by mucosal vaccines.
  • Case studies on mucosal vaccines in clinical trials (e.g., for influenza, rotavirus, and HIV).
  • Challenges in developing mucosal vaccines for emerging pathogens.
  • Computational modeling and bioinformatics in mucosal vaccine design.

We look forward to receiving your contributions.

Dr. Xingmin Sun
Dr. Yongqun He (Oliver)
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mucosal immunity
  • vaccine
  • mucosal adjuvant

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 2786 KiB  
Article
Effect of Anti-Programmed Cell Death-1 Antibody on Middle Ear Mucosal Immune Response to Intranasal Administration of Haemophilus influenzae Outer Membrane Protein
by Kazuhiro Yoshinaga, Takashi Hirano, Shingo Umemoto, Yoshinori Kadowaki, Takayuki Matsunaga and Masashi Suzuki
Vaccines 2025, 13(3), 313; https://doi.org/10.3390/vaccines13030313 - 13 Mar 2025
Viewed by 573
Abstract
Background/Objectives: Acute otitis media is a common pediatric infection caused primarily by nontypeable Haemophilus influenzae. With rising antibiotic resistance, vaccines are essential for combating this public health issue. Although the PD-1/PD-L1 pathway has been extensively studied for its role in tumor [...] Read more.
Background/Objectives: Acute otitis media is a common pediatric infection caused primarily by nontypeable Haemophilus influenzae. With rising antibiotic resistance, vaccines are essential for combating this public health issue. Although the PD-1/PD-L1 pathway has been extensively studied for its role in tumor immunity, its impact on mucosal immunity, particularly in vaccine responses, is unclear. Methods: BALB/c mice were intranasally immunized with nontypeable H. influenzae outer membrane protein and treated with anti-PD-L1 antibodies. Immune responses were evaluated in middle ear mucosa (MEM), the cervical lymph node, and the spleen using an enzyme-linked immunosorbent assay, an enzyme-linked immunospot assay, and flow cytometry. The effects on CD4+ T cells, T follicular helper (Tfh) cells, and B-cell differentiation were analyzed. Results: Anti-PD-L1 antibody treatment increased CD3+CD4+CD185+ (CXCR5+) Tfh cells in MEM, which play a crucial role in supporting B-cell activation and antibody production. This correlated with a significant increase in IgA- and IgG-producing cells in MEM, which enhanced local bacterial clearance. Although B-cell activation and differentiation into plasmablasts were observed in MEM, no significant changes were noted in the cervical lymph node and spleen, suggesting a localized enhancement of mucosal immunity. Conclusions: Anti-PD-L1 antibodies promoted Tfh cell expansion and B-cell differentiation in MEM, leading to enhanced antibody production and improved bacterial clearance. These findings suggest that PD-L1 blockade can potentiate mucosal vaccine-induced immunity by strengthening local humoral responses. This supports its potential application in developing intranasal vaccines for acute otitis media. Full article
(This article belongs to the Special Issue Mucosal Immunity and Vaccine)
►▼ Show Figures

Figure 1

16 pages, 2640 KiB  
Article
Oral Administration of Zinc Sulfate with Intramuscular Foot-and-Mouth Disease Vaccine Enhances Mucosal and Systemic Immunity
by Min Ja Lee, Seokwon Shin, Hyeong Won Kim, Mi-Kyeong Ko, So Hui Park, Su-Mi Kim and Jong-Hyeon Park
Vaccines 2024, 12(11), 1268; https://doi.org/10.3390/vaccines12111268 - 9 Nov 2024
Viewed by 1290
Abstract
Background/Objectives: Foot-and-mouth disease (FMD) remains a significant global threat to livestock farming. Current commercial FMD vaccines present several challenges, including the risk of infection and adverse injection site reactions due to oil-based adjuvants. The complex immune environment of the gut-associated lymphoid tissue [...] Read more.
Background/Objectives: Foot-and-mouth disease (FMD) remains a significant global threat to livestock farming. Current commercial FMD vaccines present several challenges, including the risk of infection and adverse injection site reactions due to oil-based adjuvants. The complex immune environment of the gut-associated lymphoid tissue has the potential to induce broad and diverse immune responses. Therefore, we aimed to explore the potential of zinc sulfate as an oral adjuvant to enhance intestinal mucosal immunity and complement the effects of intramuscular (IM) FMD vaccination. Methods: We conducted serological analyses on mice and pigs, measuring secretory IgA (sIgA) levels and evaluating the expression of mucosal immunity-related genes in pigs. These assessments were used to investigate the systemic and mucosal immune responses induced by oral zinc sulfate administration in combination with an IM FMD vaccine. Results: This combination strategy significantly increased structural protein antibody titers and virus neutralization titers in experimental animals (mice) and target animals (pigs) across early, mid-, and long-term periods. Additionally, this approach enhanced the expression of key cytokines associated with mucosal immunity and increased sIgA levels, which are critical markers of mucosal immunity. Conclusions: Oral zinc sulfate administration may synergize with inactivated FMD vaccines, leading to sustained and enhanced long-term immune responses. This novel strategy could reduce the frequency of required vaccinations or allow for a lower antigen dose in vaccines, effectively stimulating the mucosal immune system and boosting systemic immunity. This approach has the potential to improve the overall efficacy of commercial FMD vaccines. Full article
(This article belongs to the Special Issue Mucosal Immunity and Vaccine)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop